Drug intelligence / Profile preview

FL762

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules

Overview

FL762 is a small molecule being developed by Canget BioTekpharma as a back-up compound to their lead candidate, FL118. It is specifically positioned for the treatment of prostate cancer. Like FL118, FL762 is designed to target and inhibit multiple anti-apoptotic proteins and oncogenic factors, including DDX5 (p68), survivin, Mcl-1, XIAP, and cIAP2, as well as mutant Kras (mKras). By simultaneously downregulating these key survival and resistance factors, FL762 aims to overcome drug resistance and induce apoptosis in cancer cells. It is currently in the preclinical stage of development.

Targets

BIRC5 (Survivin)DDX5 (Phosphorylated-p68 RNA helicase)KRAS (Kirsten rat sarcoma viral oncogene homolog)MCL1 (Myeloid cell leukemia sequence 1)XIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)

Beyond the preview

Go deeper on FL762.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL762.